Page last updated: 2024-10-31

metyrapone and Glioblastoma

metyrapone has been researched along with Glioblastoma in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonanni, G1

Other Studies

1 other study available for metyrapone and Glioblastoma

ArticleYear
[Evaluation of the pituitary ACTH reserve in patients irradiated for cerebral neoplasms].
    Nuntius radiologicus, 1968, Volume: 34, Issue:5

    Topics: Acromegaly; Adrenocorticotropic Hormone; Adult; Astrocytoma; Brain Neoplasms; Cushing Syndrome; Fema

1968